$SNTI
Senti Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000185427024000116 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.247M
YoY Change -33.75%
% of Gross Profit
Research & Development $8.655M
YoY Change -4.81%
% of Gross Profit
Depreciation & Amortization $946.0K
YoY Change -29.93%
% of Gross Profit
Operating Expenses $15.22M
YoY Change -65.59%
Operating Profit -$15.22M
YoY Change -65.32%
Interest Expense $150.0K
YoY Change -74.27%
% of Operating Profit
Other Income/Expense, Net -$13.65M
YoY Change -288.0%
Pretax Income -$28.87M
YoY Change -21.17%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$28.87M
YoY Change 93.43%
Net Earnings / Revenue
Basic Earnings Per Share -$6.31
Diluted Earnings Per Share -$6.31
COMMON SHARES
Basic Shares Outstanding 4.589M shares 4.579M shares
Diluted Shares Outstanding 4.577M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.48M
YoY Change -73.4%
Cash & Equivalents $10.50M
Short-Term Investments
Other Short-Term Assets $8.000K
YoY Change -98.36%
Inventory
Prepaid Expenses $1.481M
Receivables $74.00K
Other Receivables $1.113M
Total Short-Term Assets $17.38M
YoY Change -78.0%
LONG-TERM ASSETS
Property, Plant & Equipment $22.22M
YoY Change -15.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $88.00K
YoY Change -50.28%
Total Long-Term Assets $40.34M
YoY Change -23.54%
TOTAL ASSETS
Total Short-Term Assets $17.38M
Total Long-Term Assets $40.34M
Total Assets $57.72M
YoY Change -56.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $793.0K
YoY Change -60.17%
Accrued Expenses $7.464M
YoY Change 13.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $103.0K
YoY Change 3.0%
Total Short-Term Liabilities $9.064M
YoY Change -10.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.543M
YoY Change -93.43%
Total Long-Term Liabilities $2.543M
YoY Change -93.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.064M
Total Long-Term Liabilities $2.543M
Total Liabilities $41.73M
YoY Change -14.55%
SHAREHOLDERS EQUITY
Retained Earnings -$296.5M
YoY Change 31.43%
Common Stock $1.000K
YoY Change -75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.99M
YoY Change
Total Liabilities & Shareholders Equity $57.72M
YoY Change -56.19%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$28.87M
YoY Change 93.43%
Depreciation, Depletion And Amortization $946.0K
YoY Change -29.93%
Cash From Operating Activities -$7.866M
YoY Change -48.86%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $60.00K
YoY Change -99.74%
Cash From Investing Activities $60.00K
YoY Change -99.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.440M
YoY Change -8233.33%
NET CHANGE
Cash From Operating Activities -7.866M
Cash From Investing Activities 60.00K
Cash From Financing Activities 2.440M
Net Change In Cash -5.366M
YoY Change -193.48%
FREE CASH FLOW
Cash From Operating Activities -$7.866M
Capital Expenditures $0.00
Free Cash Flow -$7.866M
YoY Change -54.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22218000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25338000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14470000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16274000 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
583000 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
338000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
313000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
25691000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Registrant Name
EntityRegistrantName
Senti Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2437900
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4588645 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10479000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35926000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
66913000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-28866000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7606000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
82936000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4569900 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4569900 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
312517000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
311256000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1978000 usd
CY2024Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
56094000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001854270
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
239-2030
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SNTI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 us-gaap Assets
Assets
119484000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
793000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1250000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
103000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
97000 usd
CY2023Q4 snti Early Exercise Liability Current
EarlyExerciseLiabilityCurrent
135000 usd
CY2024Q3 snti Deferred Sublease Income
DeferredSubleaseIncome
639000 usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6331000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Corporate Drive, First Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 us-gaap Assets Current
AssetsCurrent
17384000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
71200000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
3561000 usd
CY2024Q3 snti Contingent Consideration Receivable
ContingentConsiderationReceivable
0 usd
CY2023Q4 snti Contingent Consideration Receivable
ContingentConsiderationReceivable
1816000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
88000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
215000 usd
CY2024Q3 us-gaap Assets
Assets
57721000 usd
CY2024Q3 snti Early Exercise Liability Current
EarlyExerciseLiabilityCurrent
45000 usd
CY2023Q4 snti Deferred Sublease Income
DeferredSubleaseIncome
989000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2978000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5927000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4486000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4031000 usd
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
20000 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2024Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
243000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9064000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12672000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30120000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33538000 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4586957 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
255000 usd
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
83000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8655000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9092000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6247000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9431000 usd
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.31
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days
ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays
P20D
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
3522000 usd
CY2024Q3 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
0 usd
CY2023Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1119000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2543000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
20000 usd
CY2024Q3 snti Early Exercise Liability Noncurrent
EarlyExerciseLiabilityNoncurrent
0 usd
CY2023Q4 snti Early Exercise Liability Noncurrent
EarlyExerciseLiabilityNoncurrent
10000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
41727000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
52571000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4586957 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296524000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244344000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
15994000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
66913000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57721000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119484000 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
2561000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26584000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23028000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17975000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27871000 usd
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
313000 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
25691000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
15215000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
44214000 usd
us-gaap Operating Expenses
OperatingExpenses
44872000 usd
us-gaap Operating Expenses
OperatingExpenses
76590000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15215000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43876000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-44872000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-74029000 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
150000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
583000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
718000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2438000 usd
CY2024Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-207000 usd
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
1657000 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
899000 usd
us-gaap Sublease Income
SubleaseIncome
4705000 usd
us-gaap Sublease Income
SubleaseIncome
899000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13651000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7261000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7308000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9311000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-28866000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-36615000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-52180000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-64718000 usd
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
21692000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
12376000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-28866000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14923000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52180000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52342000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28866000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14923000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52180000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52343000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.31
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.31
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-8.24
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-8.24
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-11.41
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-11.41
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-14.62
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-14.62
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
4.88
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.88
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
2.80
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
2.80
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.36
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.82
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4577122 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4577122 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4447223 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4447223 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4573307 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4573307 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4427458 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4427458 shares
CY2024Q1 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1258000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12111000 usd
CY2024Q2 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
33000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-776000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11203000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
44148000 usd
CY2024Q3 snti Stock Issued During Period Value Purchase Agreement Fee Settled In Stock
StockIssuedDuringPeriodValuePurchaseAgreementFeeSettledInStock
10000 usd
CY2024Q3 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
668000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
15994000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
127263000 usd
CY2023Q1 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3763000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18722000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
112340000 usd
CY2023Q2 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
308000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3434000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18697000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
97416000 usd
CY2023Q3 snti Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
34000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
409000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14923000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52180000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52342000 usd
us-gaap Depreciation
Depreciation
2901000 usd
us-gaap Depreciation
Depreciation
2569000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1491000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1386000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1069000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
21862000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-207000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
313000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
25691000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1150000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7606000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-107000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
98000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-21000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-442000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
465000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2702000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1195000 usd
snti Increase Decrease In Deferred Sublease Income
IncreaseDecreaseInDeferredSubleaseIncome
-350000 usd
snti Increase Decrease In Deferred Sublease Income
IncreaseDecreaseInDeferredSubleaseIncome
747000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-799000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2963000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
114000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
113000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27893000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45358000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
17990000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
60000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12034000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
60000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29976000 usd
snti Net Proceeds From Grant
NetProceedsFromGrant
2430000 usd
snti Net Proceeds From Grant
NetProceedsFromGrant
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
308000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
85000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2440000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
223000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25408000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15159000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39448000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60987000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14040000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45828000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10479000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39430000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
3561000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
6398000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14040000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45828000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000 usd
snti Receivable In Prepaid Expenses And Other Current Assets
ReceivableInPrepaidExpensesAndOtherCurrentAssets
52000 usd
snti Receivable In Prepaid Expenses And Other Current Assets
ReceivableInPrepaidExpensesAndOtherCurrentAssets
0 usd
snti Cash Acquired Through Reverse Recapitalization
CashAcquiredThroughReverseRecapitalization
302500000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296500000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52300000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10500000 usd
snti Number Of Business Activities
NumberOfBusinessActivities
1 businessactivitiy
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 reportablesegment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of GeneFab Option, the valuation of GeneFab Economic Share, the valuation of the GeneFab Note Receivable, the discount rate used to discount future cash flows for the impairment of long-lived assets, and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and restricted cash are maintained in checking and money market accounts at multiple financial institutions, which at times, may exceed federally insured limits. As of September 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company has prepaid future manufacturing and research services of $3.9 million under an agreement with GeneFab for certain development and manufacturing services agreement which are recorded in GeneFab prepaid expenses - related party in the condensed consolidated balance sheets and $1.1 million receivable related to general and administrative services provided under the transition services agreement which are recorded in GeneFab receivable - related party in the condensed consolidated balance sheets . The prepaid expenses and receivable balances from GeneFab potentially subject the Company to a significant concentration of credit risk if the Company is unable to realize these balances. Refer to Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GeneFab Transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the GeneFab transaction.</span></div>
us-gaap Asset Impairment Charges
AssetImpairmentCharges
25700000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14040000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14040000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39448000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39448000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1481000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2546000 usd
CY2024Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
357000 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
42000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
8000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
195000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30846000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31520000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8628000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6182000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22218000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25338000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1571000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3555000 usd
CY2024Q3 snti Accrued Professional Fees Other Current
AccruedProfessionalFeesOtherCurrent
1369000 usd
CY2023Q4 snti Accrued Professional Fees Other Current
AccruedProfessionalFeesOtherCurrent
2363000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2978000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5927000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1312000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1323000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3943000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3952000 usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
26000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
64000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
268000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
272000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
771000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
894000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
1589000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
1603000 usd
us-gaap Lease Cost
LeaseCost
4740000 usd
us-gaap Lease Cost
LeaseCost
4910000 usd
snti Operating Lease Proceeds Payments
OperatingLeaseProceedsPayments
-5412000 usd
snti Operating Lease Proceeds Payments
OperatingLeaseProceedsPayments
-2449000 usd
snti Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Adjustments
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfAdjustments
0 usd
snti Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Adjustments
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfAdjustments
13000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y10M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1839000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7478000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7712000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5769000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4855000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
14529000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
47182000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12576000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
34606000 usd
CY2024Q3 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
1314000 usd
CY2023Q3 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
0 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
3757000 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
0 usd
CY2024Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
343000 usd
CY2023Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
0 usd
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
948000 usd
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
0 usd
CY2024Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1657000 usd
CY2023Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
4705000 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0 usd
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
300000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
1205000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
5339000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
5472000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
5053000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
4891000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Five Years
LessorOperatingLeasePaymentsToBeReceivedFiveYears
5037000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
13258000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
40255000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 snti Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1 vote
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4640788 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4483216 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Shares
ReverseRecapitalizationContingentConsiderationEquityShares
200000 shares
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Number Of Tranches
ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches
2 tranche
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche
ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche
100000 shares
CY2022Q2 snti Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days
ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays
P30D
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-200000 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
100000 usd
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
100000 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
200000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
800000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
668000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
409000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1150000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3500000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
0 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-28866000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-36615000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-52180000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-64718000 usd
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
21692000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
12376000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-28866000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14923000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52180000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52342000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4577122 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4577122 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4447223 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4447223 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4573307 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4573307 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4427458 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4427458 shares
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.31
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.31
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-8.24
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-8.24
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-11.41
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-11.41
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-14.62
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-14.62
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
4.88
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.88
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
2.80
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
2.80
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.31
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.36
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.82
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3149595 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3387061 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3149595 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3387061 shares
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001854270-24-000116-index-headers.html Edgar Link pending
0001854270-24-000116-index.html Edgar Link pending
0001854270-24-000116.txt Edgar Link pending
0001854270-24-000116-xbrl.zip Edgar Link pending
a2024093010qex311.htm Edgar Link pending
a2024093010qex312.htm Edgar Link pending
a2024093010qex321.htm Edgar Link pending
a2024093010qex322.htm Edgar Link pending
a20240930ex102sublease-bkp.htm Edgar Link pending
a20240930ex103-storagelice.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snti-20240930.htm Edgar Link pending
snti-20240930.xsd Edgar Link pending
snti-20240930_cal.xml Edgar Link unprocessable
snti-20240930_def.xml Edgar Link unprocessable
snti-20240930_lab.xml Edgar Link unprocessable
snti-20240930_pre.xml Edgar Link unprocessable
snti-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable